Barrett's Esophagus Ablation Devices Market Report | United States | 2019-2025 | MedCore
|発行||iData Research Inc.||商品コード||379009|
|出版日||ページ情報||英文 72 Pages
|米国のバレット食道切除装置市場 Barrett's Esophagus Ablation Devices Market Report | United States | 2019-2025 | MedCore|
|出版日: 2019年02月01日||ページ情報: 英文 72 Pages||
Barrett's esophagus is a condition in which the tissue of the lower esophagus is replaced by epithelial cells that are similar to ones found in the small intestine. Individuals with Barrett's esophagus have a higher risk of developing esophageal adenocarcinoma. This type of cancer is often associated with low survival rates. Barrett's esophagus has a higher prevalence among individuals who suffer from gastroesophageal reflux disease (GERD). It is thought that constant exposure to acid is a cause of the metaplasia of the cells in the lower esophagus, which is the cause of Barrett's esophagus.
Unit sales growth will be driven by an expansion in installed base and replacement sales of devices that have reached the end of their lifespan. Based on available purchase order data, prices varied significantly between manufacturers in 2018. Medtronic's Barrx™ system was priced between $120,000 and $140,000 and CSA Medical's truFreeze® was priced between $70,000 and $80,000. These prices do not reflect the true pricing, as is evident in the ASP reported between $31,000 and $32,000. Medtronic and CSA Medical tend to incorporate bundling deals with their disposable products, which explains the discrepancy between the purchase order data and reported ASP.
BARRETT'S ESOPHAGUS ABLATION DEVICE MARKET 49